Radiation Oncology/Therapy: Page 199

PET/MRI tops PET/CT in abdominopelvic lesion conspicuity
By Wayne Forrest
Wednesday, November 28 | 11:50 a.m.-12:00 p.m. | SSK08-09 | Room S504CDPET/MRI with ultrafast gradient-recalled echo and spin-echo sequences is superior to PET/CT for lesion conspicuity, thus potentially improving therapy for patients with abdominopelvic cancer, according to a study by Swiss researchers.
November 7, 2012
FDG-PET/CT helps assess pancreatic cancer recurrence
By Wayne Forrest
Wednesday, November 28 | 11:30 a.m.-11:40 a.m. | SSK13-07 | Room S505ABFDG-PET/CT has "excellent accuracy" in detecting a recurrence following resection of pancreatic cancer, and maximum standardized uptake values can be used in determining the prognosis of these patients, according to researchers from India.
November 7, 2012
FDG-PET/CT plays key role in treatment outcomes of prostate cancer
By Wayne Forrest
Wednesday, November 28 | 11:00 a.m.-11:10 a.m. | SSK13-04 | Room S505ABA preliminary study by researchers at the University of Southern California suggests that FDG-PET/CT provides unique prognostic information on outcomes for men with castrate-sensitive metastatic prostate cancer who are undergoing various forms of hormonal treatment.
November 7, 2012
PET/MRI outshines PET/CT in lesion detection
By Wayne Forrest
Monday, November 26 | 11:00 a.m.-11:10 a.m. | SSC13-04 | Room S505ABPET/MRI showed superior lesion detectability compared to contrast-enhanced PET/CT in this study from King Fahad Specialist Hospital in Dammam, Saudi Arabia. Based on the results, researchers concluded that PET/MRI may be useful for abdominal lesion staging while sparing patients from contrast media.
November 7, 2012
NaF-PET/CT detects more skeletal lesions in advanced breast cancer cases
By Wayne Forrest
Monday, November 26 | 11:00 a.m.-11:10 a.m. | SSC09-04 | Room S504CDF-18 sodium fluoride (NaF) PET/CT detects more skeletal lesions than technetium-99m methylene diphosphonate SPECT in patients newly diagnosed with breast cancer, according to researchers from India.
November 7, 2012
FDG-PET/CT predicts response to chemo in breast cancer patients
By Wayne Forrest
Sunday, November 25 | 11:55 a.m.-12:05 p.m. | SSA18-08 | Room S505ABIn this presentation, Japanese researchers will discuss the ability of FDG tumor uptake at baseline and after neoadjuvant chemotherapy to predict pathological complete response and disease-free survival after surgery.
November 7, 2012
PET/CT helps with bone scans in staging breast cancer
By Wayne Forrest
Sunday, November 25 | 11:45 a.m.-11:55 a.m. | SSA18-07 | Room S505ABPET/CT can provide sufficient information from bone scans for the staging or restaging of breast cancer, according to a retrospective study by researchers from University Hospital Mannheim.
November 7, 2012
PET/MRI offers diagnostic accuracy for lymph node staging
By Wayne Forrest
Sunday, November 25 | 11:15 a.m.-11:25 a.m. | SSA12-04 | Room S504CDPET/MRI provides sufficient diagnostic accuracy for lymph node metastases detection, while diffusion-weighted MRI images are inaccurate for staging in head and neck cancer patients, according to researchers from the University of Düsseldorf.
November 7, 2012
Antidepressant rinse reduces pain for cancer patients after RT
By Cynthia E. Keen
When used as a rinse, doxepin, a tricyclic antidepressant, reduces oral mucositis pain in patients who receive radiation therapy (RT) for head and neck cancer, according to research from the Mayo Clinic presented at the recent American Society for Radiation Oncology annual meeting.
November 6, 2012
Elastography offers alternative for evaluating soft-tissue lesions
By Kate Madden Yee
Tuesday, November 27 | 5:00 p.m.-5:30 p.m. | LL-MKS-TU4C | Lakeside Learning CenterUltrasound elastography could be a useful tool for evaluating superficial soft-tissue lesions, according to this Tuesday poster presentation from Italian researchers.
November 6, 2012
CEUS comparable to MDCT for managing colorectal cancer patients
By Kate Madden Yee
Sunday, November 25 | 12:30 p.m.-1:00 p.m. | LL-GIS-SU2A | Lakeside Learning CenterContrast-enhanced ultrasound (CEUS) is comparable to MDCT in assessing patients undergoing antiangiogenic drug-based neoadjuvant therapy for colorectal cancer liver metastasis, according researchers from Italy.
November 6, 2012
US, MRI tumor measurements can predict residual disease
By Kate Madden Yee
Sunday, November 25 | 12:30 p.m.-1:00 p.m. | LL-BRS-SU5A | Lakeside Learning CenterHow best can doctors assess residual disease in inflammatory breast cancer patients who have undergone neoadjuvant chemotherapy? Find out in this Sunday poster presentation.
November 6, 2012
Previous Page
Page 199 of 464
Next Page